Masimo Corp (MASI) 24.05 $MASI
Masimo Announces CE Mark and Limited Market Release of Radius-7(TM) -- First rainbow(R) SET(R) Noninvasive Wearable, Wireless Monitor for Root(R)
Marketwire - Tue Jul 29, 1:00AM CDT
Masimo (NASDAQ: MASI) today announced CE Mark and limited market release of Radius-7(TM) for the Root(R) patient monitoring and connectivity platform, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow(R) SET(R) technology, enabling early identification of clinical deterioration while offering patients continuous monitoring with freedom of movement.
mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis to 2019
M2 - Tue Jul 22, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8tjcf/mhealth) has announced the addition of the "mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" report to their offering. According to The Center for Technology and Aging, the U.S. healthcare system could reduce the cost of healthcare expenditure by approximately USD 200 billion in the next 25 years through the implementation of remote patient monitoring technologies. Hence, this report is focused towards identifying the current scenario as well as the future market potential for mHealth monitoring and diagnostic devices, globally, with a special focus on medical devices like smartphones and tablets. The mHealth monitoring and diagnostic devices market has been segmented into seven major product types, namely, glucose monitors, blood pressure monitors, pulse oximeters, cardiac monitors, sleep apnea monitors, multi-parameter monitoring devices and other monitoring devices (fetal monitors, neurological monitors, asthma monitoring devices). These monitors are used for monitoring and diagnosing health and wellness of a patient via connectivity with the smartphones or tablets that enable data transfer to healthcare professionals via Bluetooth, NFC, Wi-Fi or USB stick. Of all the above mentioned monitoring and diagnostic devices, glucose monitors have been anticipated as the fastest growing segment for the forecast period 2013 to 2019, at a CAGR of 49.4%. According to the International Diabetes Federation (IDF), the number of people suffering globally from diabetes is around 392 million in 2013 and is expected to rise to 592 million by 2035. Hence, fastest growth rate of this segment is identified on the basis of year-on-year growth of diabetic patients globally and rising demand for invasive and minimally invasive glucose monitoring devices. In addition, global increase in number of smartphones and turnaround innovations in the mobile health devices, owing to improved technology are other important drivers of this market. Multi-parameter monitoring devices are also expected to witness significant growth rate in near future due to increasing awareness about health and fitness in developed countries. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global mHealth Monitoring and Diagnostic Medical Devices Market, by Product Type Chapter 5 Global mHealth Monitoring and Diagnostic Medical Devices Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Bayer HealthCare AG - BioTelemetry, Inc. (CardioNet, Inc.) - Boston Scientific Corporation - DexCom, Inc. - Dr?ger AG - F. Hoffmann-La Roche Ltd. - FitBit, Inc. - Fora Care Inc. - iHealth Labs, Inc. - Johnson & Johnson - LifeWatch AG - Masimo Corporation - Medisana AG - Medtronic, Inc. - Nonin Medical, Inc. - Omron Healthcare, Inc. - Withings, Inc. For more information visit http://www.researchandmarkets.com/research/f8tjcf/mhealth
Thermo Fisher Wins 3 Oscars of Innovation, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 4:20PM CDT
Following the news, Thermo Fisher's (TMO) share price gained 1.7% to eventually close at $121.00 on Friday.
Masimo to Report Second Quarter 2014 Financial Results After Market Close on Thursday, August 7th
Marketwire - Mon Jul 21, 3:30PM CDT
Masimo (NASDAQ: MASI) announced today that it will release financial results for the second quarter ended June 28, 2014, after the market closes on Thursday, August 7, 2014. The release and conference call date is approximately one week later than Masimo's traditional release timing due to executive calendar conflicts during the month of July. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Mark P. de Raad, Executive Vice President and Chief Financial Officer.
Cepheid Slumps: CPHD Tumbles 9.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:37AM CDT
Cepheid has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past one day
Thermo Fisher (TMO) to Divest Cole-Parmer to GTCR for $480M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:55PM CDT
Thermo Fisher Scientific (TMO) recently inked a definitive agreement with private equity firm GTCR, LLC.
Varian Medical's Radiosurgery Offers Precise Cancer Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:06PM CDT
Varian Medical Systems, Inc.'s (VAR) Edge radiosurgery system is a fast, precise and non-invasive alternative to conventional surgery for the treatment of patients with lung, prostate, spine and brain tumors.
IDEXX Poised on Strong Global Companion Animal Group Growth (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 1:19PM CDT
IDEXX reported mixed first-quarter 2014 results with its bottom line steering ahead of the Zacks Consensus Estimate and revenues missing our expectation.
Cepheid Posts Narrower-than-Expected Q2 Loss, Revenues Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 10:40AM CDT
Cepheid (CPHD) experienced robust 21.3% year-over-year growth in revenues of $116.5 million in the second quarter
IDEXX Poised on Strong Global Companion Animal Group Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 5:30PM CDT
On Jul 16, 2014, we initiated coverage on IDEXX Laboratories, Inc. (IDXX).
New Born Screening Market Report 2014: Test Type, Technology, Instrument, Accessories, Reagent & Assay Kit Analysis
M2 - Wed Jul 16, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jrfdhj/newborn_screening) has announced the addition of the "NewBorn Screening Market by Test Type, Technology, Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019" report to their offering. The global newborn screening market was valued at an estimated $438.9 million in 2013 and is expected to grow at a CAGR of 11.0% in the next five years. This high growth is mainly attributed to the benefits offered by newborn screening programs, legislations and mandates, technological advancements, government support, and expanding panel of newborn diseases, and conferences and symposiums related to the usage of new technologies. Furthermore, various awareness programs and conferences are being organized across the globe, which is likely to drive the market growth. However, factors such as lack of trained professional infrastructure and socio-economic barriers are expected to hinder the market growth. North America dominates the newborn screening market. Asia is poised to grow at the highest CAGR during the forecast period owing to support provided by foreign countries for enhancing screening services. Apart from this, factors such as increased government support and investment by major players in the region are expected to provide required impetus for the growth of this market. This report categorizes the global newborn screening market on the basis of test type, technology, product, and geography. The mass spectrometry market is expected to register the highest growth rate in the newborn screening market by technology, during the forecast period. This high growth is attributed to various nations opting for expanded newborn screening. Tandem mass spectrometry is a fundamental instrument used for expanded newborn screening. Furthermore, various conferences and symposiums are being conducted to spread awareness for the use of such technologies. For instance, in May 2013, the Joint Meeting of the Newborn Screening and Genetic Testing Symposium was organized in Atlanta. The symposium was aimed to discuss national and international newborn screening, genetic testing, and policy issues. Scope of the Report By Test Type - Dry Blood Spot Test - Hearing Screen Test - Critical Congenital Heart Disease (CCHD) Test By Technology - Tandem Mass Spectrometry - Electrophoresis - Enzymes and Immunoassays - DNA-based Assays - Hearing Screen Technology - Pulse Oximetry Technology By Product - Instruments - Newborn Disorder Screening Instruments - Hearing Screening Instruments - Hearing Screening Devices - Hearing Screening Accessories - Pulse Oximetry Instruments - Reagents and Assay Kits Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Newborn Screening Market, By Test Type 6 Newborn Screening Market, By Technology 7 Newborn Screening Market, By Product Type 8 Newborn Screening Market, By Geography 9 Competitive Landscape 10 Company Profiles - AB Sciex LLC (A Subsidiary of Danaher Corporation) - Agilent Technologies Inc. - Bio-Rad Laboratories, Inc. - Covidien Plc - GE Healthcare (Subsidiary of General Electric Company) - Masimo Corporation - Natus Medical Incorporated - Perkinelmer, Inc. - Trivitron Healthcare - Waters Corporation For more information visit http://www.researchandmarkets.com/research/jr..._screening
CE Mark for Boston Scientific's Peripheral Vascular Device - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 5:20PM CDT
Boston Scientific Corporation (BSX) recently received CE Mark approval and is proceeding with the full European market launch of the Ranger Paclitaxel-Coated PTA Balloon Catheter.
Varian Medical's Linear Accelerator Debuts in India - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 3:30PM CDT
Varian Medical Systems (VAR) continues to deliver revolutionary capabilities in radiotherapy and radiosurgery to advance precise, accurate and efficient treatment for cancer patients around the world.
Welch Allyn Expands Connex(R) Vital Signs Monitor with Customizable Scoring App
Business Wire - Mon Jul 14, 7:30AM CDT
Welch Allyn, a leading medical diagnostic device company that delivers pragmatic innovation at the point of care, today announced a new scoring app for its Connex(R) Vital Signs Monitor (VSM). The ability to score patient data on the Connex VSM multiparameter device using the hospital's protocols enables healthcare professionals to evaluate multiple parameters in a single score, which can include patient vitals and manually-entered assessments and measurements. The Connex(R) Scoring App(TM) can help track signs of patient deterioration at the bedside using the hospital's own Early Warning Score (EWS) protocols to determine the likelihood of adverse events. The new app uses a point-of-care calculator to automate and color code customizable bedside scoring protocols for any type of clinical issue, as well as facility-determined interventions, to help providers make informed patient care decisions quickly.
Volcano Corp. Poised on Strong IVUS Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 5:40PM CDT
On Jul 11, we issued an updated research report on Volcano Corporation (VOLC).
BioScrip's PBM Services Continue to Suffer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 6:10PM CDT
On Jul 10, we issued an updated research report on Bioscrip, Inc. (BIOS).
New Study Evaluates Trending Accuracy and Reliability of Masimo's Continuous and Noninvasive SpHb(R) Technology
Marketwire - Wed Jul 09, 5:00PM CDT
Masimo (NASDAQ: MASI) announced today that a new clinical study published in the Journal of Clinical Monitoring evaluated the relative trending accuracy of Masimo's noninvasive and continuous total hemoglobin (SpHb(R)) in patients with end-stage renal disease who underwent dialysis.(1)
Techne, Novus Biologicals Unite to Advance Life Science Research - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:40PM CDT
The acquisition of Novus Biologicals is in sync with Techne Corp.'s (TECH) objective of expanding its product offering and providing its customers with the most comprehensive products for research needs.
Why is Cyberonics Downgraded to Sell? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 2:00PM CDT
On Jul 8, Zacks Investment Research downgraded Cyberonics Inc. (CYBX) to a Zacks Rank #4 (Sell).
Upcoming Earnings, Donations, FDA Approvals, Mortality Reduction Commitments, and New Monitoring Platform - Analyst Notes on Boston Scientific, ResMed, Edwards, Masimo and NuVasive
PR Newswire - Fri Jul 04, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Boston Scientific Corporation (NYSE: BSX), ResMed Inc. (NYSE: RMD), Edwards Lifesciences Corp. (NYSE: EW), Masimo Corporation (NASDAQ: MASI) and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4460-100free.
Masimo Announces CE Mark and Limited Market Release of Radius-7(TM) -- First rainbow(R) SET(R) Noninvasive Wearable, Wireless Monitor for Root(R)
Marketwire - Tue Jul 29, 1:00AM CDT
Masimo (NASDAQ: MASI) today announced CE Mark and limited market release of Radius-7(TM) for the Root(R) patient monitoring and connectivity platform, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow(R) SET(R) technology, enabling early identification of clinical deterioration while offering patients continuous monitoring with freedom of movement.
mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis to 2019
M2 - Tue Jul 22, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8tjcf/mhealth) has announced the addition of the "mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" report to their offering. According to The Center for Technology and Aging, the U.S. healthcare system could reduce the cost of healthcare expenditure by approximately USD 200 billion in the next 25 years through the implementation of remote patient monitoring technologies. Hence, this report is focused towards identifying the current scenario as well as the future market potential for mHealth monitoring and diagnostic devices, globally, with a special focus on medical devices like smartphones and tablets. The mHealth monitoring and diagnostic devices market has been segmented into seven major product types, namely, glucose monitors, blood pressure monitors, pulse oximeters, cardiac monitors, sleep apnea monitors, multi-parameter monitoring devices and other monitoring devices (fetal monitors, neurological monitors, asthma monitoring devices). These monitors are used for monitoring and diagnosing health and wellness of a patient via connectivity with the smartphones or tablets that enable data transfer to healthcare professionals via Bluetooth, NFC, Wi-Fi or USB stick. Of all the above mentioned monitoring and diagnostic devices, glucose monitors have been anticipated as the fastest growing segment for the forecast period 2013 to 2019, at a CAGR of 49.4%. According to the International Diabetes Federation (IDF), the number of people suffering globally from diabetes is around 392 million in 2013 and is expected to rise to 592 million by 2035. Hence, fastest growth rate of this segment is identified on the basis of year-on-year growth of diabetic patients globally and rising demand for invasive and minimally invasive glucose monitoring devices. In addition, global increase in number of smartphones and turnaround innovations in the mobile health devices, owing to improved technology are other important drivers of this market. Multi-parameter monitoring devices are also expected to witness significant growth rate in near future due to increasing awareness about health and fitness in developed countries. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global mHealth Monitoring and Diagnostic Medical Devices Market, by Product Type Chapter 5 Global mHealth Monitoring and Diagnostic Medical Devices Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Bayer HealthCare AG - BioTelemetry, Inc. (CardioNet, Inc.) - Boston Scientific Corporation - DexCom, Inc. - Dr?ger AG - F. Hoffmann-La Roche Ltd. - FitBit, Inc. - Fora Care Inc. - iHealth Labs, Inc. - Johnson & Johnson - LifeWatch AG - Masimo Corporation - Medisana AG - Medtronic, Inc. - Nonin Medical, Inc. - Omron Healthcare, Inc. - Withings, Inc. For more information visit http://www.researchandmarkets.com/research/f8tjcf/mhealth
Thermo Fisher Wins 3 Oscars of Innovation, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 4:20PM CDT
Following the news, Thermo Fisher's (TMO) share price gained 1.7% to eventually close at $121.00 on Friday.
Masimo to Report Second Quarter 2014 Financial Results After Market Close on Thursday, August 7th
Marketwire - Mon Jul 21, 3:30PM CDT
Masimo (NASDAQ: MASI) announced today that it will release financial results for the second quarter ended June 28, 2014, after the market closes on Thursday, August 7, 2014. The release and conference call date is approximately one week later than Masimo's traditional release timing due to executive calendar conflicts during the month of July. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Mark P. de Raad, Executive Vice President and Chief Financial Officer.
Cepheid Slumps: CPHD Tumbles 9.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:37AM CDT
Cepheid has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past one day
Thermo Fisher (TMO) to Divest Cole-Parmer to GTCR for $480M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:55PM CDT
Thermo Fisher Scientific (TMO) recently inked a definitive agreement with private equity firm GTCR, LLC.
Varian Medical's Radiosurgery Offers Precise Cancer Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:06PM CDT
Varian Medical Systems, Inc.'s (VAR) Edge radiosurgery system is a fast, precise and non-invasive alternative to conventional surgery for the treatment of patients with lung, prostate, spine and brain tumors.
IDEXX Poised on Strong Global Companion Animal Group Growth (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 1:19PM CDT
IDEXX reported mixed first-quarter 2014 results with its bottom line steering ahead of the Zacks Consensus Estimate and revenues missing our expectation.
Cepheid Posts Narrower-than-Expected Q2 Loss, Revenues Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 10:40AM CDT
Cepheid (CPHD) experienced robust 21.3% year-over-year growth in revenues of $116.5 million in the second quarter
IDEXX Poised on Strong Global Companion Animal Group Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 5:30PM CDT
On Jul 16, 2014, we initiated coverage on IDEXX Laboratories, Inc. (IDXX).
New Born Screening Market Report 2014: Test Type, Technology, Instrument, Accessories, Reagent & Assay Kit Analysis
M2 - Wed Jul 16, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jrfdhj/newborn_screening) has announced the addition of the "NewBorn Screening Market by Test Type, Technology, Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019" report to their offering. The global newborn screening market was valued at an estimated $438.9 million in 2013 and is expected to grow at a CAGR of 11.0% in the next five years. This high growth is mainly attributed to the benefits offered by newborn screening programs, legislations and mandates, technological advancements, government support, and expanding panel of newborn diseases, and conferences and symposiums related to the usage of new technologies. Furthermore, various awareness programs and conferences are being organized across the globe, which is likely to drive the market growth. However, factors such as lack of trained professional infrastructure and socio-economic barriers are expected to hinder the market growth. North America dominates the newborn screening market. Asia is poised to grow at the highest CAGR during the forecast period owing to support provided by foreign countries for enhancing screening services. Apart from this, factors such as increased government support and investment by major players in the region are expected to provide required impetus for the growth of this market. This report categorizes the global newborn screening market on the basis of test type, technology, product, and geography. The mass spectrometry market is expected to register the highest growth rate in the newborn screening market by technology, during the forecast period. This high growth is attributed to various nations opting for expanded newborn screening. Tandem mass spectrometry is a fundamental instrument used for expanded newborn screening. Furthermore, various conferences and symposiums are being conducted to spread awareness for the use of such technologies. For instance, in May 2013, the Joint Meeting of the Newborn Screening and Genetic Testing Symposium was organized in Atlanta. The symposium was aimed to discuss national and international newborn screening, genetic testing, and policy issues. Scope of the Report By Test Type - Dry Blood Spot Test - Hearing Screen Test - Critical Congenital Heart Disease (CCHD) Test By Technology - Tandem Mass Spectrometry - Electrophoresis - Enzymes and Immunoassays - DNA-based Assays - Hearing Screen Technology - Pulse Oximetry Technology By Product - Instruments - Newborn Disorder Screening Instruments - Hearing Screening Instruments - Hearing Screening Devices - Hearing Screening Accessories - Pulse Oximetry Instruments - Reagents and Assay Kits Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Newborn Screening Market, By Test Type 6 Newborn Screening Market, By Technology 7 Newborn Screening Market, By Product Type 8 Newborn Screening Market, By Geography 9 Competitive Landscape 10 Company Profiles - AB Sciex LLC (A Subsidiary of Danaher Corporation) - Agilent Technologies Inc. - Bio-Rad Laboratories, Inc. - Covidien Plc - GE Healthcare (Subsidiary of General Electric Company) - Masimo Corporation - Natus Medical Incorporated - Perkinelmer, Inc. - Trivitron Healthcare - Waters Corporation For more information visit http://www.researchandmarkets.com/research/jr..._screening
CE Mark for Boston Scientific's Peripheral Vascular Device - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 5:20PM CDT
Boston Scientific Corporation (BSX) recently received CE Mark approval and is proceeding with the full European market launch of the Ranger Paclitaxel-Coated PTA Balloon Catheter.
Varian Medical's Linear Accelerator Debuts in India - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 3:30PM CDT
Varian Medical Systems (VAR) continues to deliver revolutionary capabilities in radiotherapy and radiosurgery to advance precise, accurate and efficient treatment for cancer patients around the world.
Welch Allyn Expands Connex(R) Vital Signs Monitor with Customizable Scoring App
Business Wire - Mon Jul 14, 7:30AM CDT
Welch Allyn, a leading medical diagnostic device company that delivers pragmatic innovation at the point of care, today announced a new scoring app for its Connex(R) Vital Signs Monitor (VSM). The ability to score patient data on the Connex VSM multiparameter device using the hospital's protocols enables healthcare professionals to evaluate multiple parameters in a single score, which can include patient vitals and manually-entered assessments and measurements. The Connex(R) Scoring App(TM) can help track signs of patient deterioration at the bedside using the hospital's own Early Warning Score (EWS) protocols to determine the likelihood of adverse events. The new app uses a point-of-care calculator to automate and color code customizable bedside scoring protocols for any type of clinical issue, as well as facility-determined interventions, to help providers make informed patient care decisions quickly.
Volcano Corp. Poised on Strong IVUS Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 5:40PM CDT
On Jul 11, we issued an updated research report on Volcano Corporation (VOLC).
BioScrip's PBM Services Continue to Suffer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 6:10PM CDT
On Jul 10, we issued an updated research report on Bioscrip, Inc. (BIOS).
New Study Evaluates Trending Accuracy and Reliability of Masimo's Continuous and Noninvasive SpHb(R) Technology
Marketwire - Wed Jul 09, 5:00PM CDT
Masimo (NASDAQ: MASI) announced today that a new clinical study published in the Journal of Clinical Monitoring evaluated the relative trending accuracy of Masimo's noninvasive and continuous total hemoglobin (SpHb(R)) in patients with end-stage renal disease who underwent dialysis.(1)
Techne, Novus Biologicals Unite to Advance Life Science Research - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:40PM CDT
The acquisition of Novus Biologicals is in sync with Techne Corp.'s (TECH) objective of expanding its product offering and providing its customers with the most comprehensive products for research needs.
Why is Cyberonics Downgraded to Sell? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 2:00PM CDT
On Jul 8, Zacks Investment Research downgraded Cyberonics Inc. (CYBX) to a Zacks Rank #4 (Sell).
Upcoming Earnings, Donations, FDA Approvals, Mortality Reduction Commitments, and New Monitoring Platform - Analyst Notes on Boston Scientific, ResMed, Edwards, Masimo and NuVasive
PR Newswire - Fri Jul 04, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Boston Scientific Corporation (NYSE: BSX), ResMed Inc. (NYSE: RMD), Edwards Lifesciences Corp. (NYSE: EW), Masimo Corporation (NASDAQ: MASI) and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4460-100free.
